Subscribe

What are you looking for?

Main Menu

明報新聞網

中國生物醫藥出口管制修訂較傳聞寬鬆　花旗料利好創新藥及醫藥研發外包行業

Future Wealths
Future Wealths
19 10 月, 2026
One Min Read
2 Views
0 Comments
花旗發表報告指出，內地放寬生物醫藥技術出口管制的修訂建議，對中國創新藥及醫藥研發外包（CRO）行業有利，因為官方最新徵求意見稿的限制較早前市場流傳的版本寬鬆。

原文: https://finance.mingpao.com/fin/instantf/20261019/1792371968158/%E4%B8%AD%E5%9C%8B%E7%94%9F%E7%89%A9%E9%86%AB%E8%97%A5%E5%87%BA%E5%8F%A3%E7%AE%A1%E5%88%B6%E4%BF%AE%E8%A8%82%E8%BC%83%E5%82%B3%E8%81%9E%E5%AF%AC%E9%AC%86-%E8%8A%B1%E6%97%97%E6%96%99%E5%88%A9%E5%A5%BD%E5%89%B5%E6%96%B0%E8%97%A5%E5%8F%8A%E9%86%AB%E8%97%A5%E7%A0%94%E7%99%BC%E5%A4%96%E5%8C%85%E8%A1%8C%E6%A5%AD%22%20target=%22blank

Last Update: 19 10 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept